☰

Tracy A. Brooks, Ph.D. - Publications

Affiliations: 
2004 State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Pharmacology, Oncology
Tree Info Grants Similar researchers PubMed Report error

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Valiuska S, Psaras AM, Noé V, Brooks TA, Ciudad CJ. Targeting MYC Regulation with Polypurine Reverse Hoogsteen Oligonucleotides. International Journal of Molecular Sciences. 24. PMID 36613820 DOI: 10.3390/ijms24010378  0.337
2022 Psaras AM, Carty RK, Miller JT, Tumey LN, Brooks TA. Indoloquinoline-Mediated Targeted Downregulation of KRAS through Selective Stabilization of the Mid-Promoter G-Quadruplex Structure. Genes. 13. PMID 36011352 DOI: 10.3390/genes13081440  0.31
2019 Morgan RK, Psaras A, Lassiter Q, Raymer K, Brooks TA. G-quadruplex deconvolution with physiological mimicry enhances primary screening: Optimizing the FRET Melt assay. Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms. 194478. PMID 31891781 DOI: 10.1016/J.Bbagrm.2019.194478  0.364
2018 Morgan RK, Molnar MM, Batra H, Summerford B, Wadkins RM, Brooks TA. Effects of 5-Hydroxymethylcytosine Epigenetic Modification on the Stability and Molecular Recognition of VEGF i-Motif and G-Quadruplex Structures. Journal of Nucleic Acids. 2018: 9281286. PMID 29862069 DOI: 10.1155/2018/9281286  0.369
2017 Hao T, Brooks TA. Abstract 2168: Nucleic acid clamp-mediated recognition and transcriptional modulation of MYC oncogenes through the stabilization of G-quadruplexes Cancer Research. 77: 2168-2168. DOI: 10.1158/1538-7445.Am2017-2168  0.417
2017 Molnar MM, Morgan RK, Brooks TA, Wadkins RM. Effects of 5-Hydroxymethylcytosine Epigenetic Modifications within the VEGF Promoter Region on G-Quadruplex and I-Motif DNA Structure and Stability Biophysical Journal. 112. DOI: 10.1016/J.Bpj.2016.11.409  0.339
2016 Hao T, Gaerig VC, Brooks TA. Nucleic acid clamp-mediated recognition and stabilization of the physiologically relevant MYC promoter G-quadruplex. Nucleic Acids Research. PMID 27789698 DOI: 10.1093/Nar/Gkw1006  0.381
2016 Hao T, Brooks T. Abstract 4514: Transcription down-regulation of c-Myc through nucleic acid clamp-mediated stabilization of the promoter G-quadruplex Cancer Research. 76: 4514-4514. DOI: 10.1158/1538-7445.Am2016-4514  0.426
2016 Morgan RK, Brooks TA. Abstract 3092: Physiological mimicry to characterize the average topology of the MYC and VEGF promoter G-quadruplexes Cancer Research. 76: 3092-3092. DOI: 10.1158/1538-7445.Am2016-3092  0.425
2016 Batra H, Islam MK, Thurston DE, Rahman KM, Brooks TA. Abstract 2914: Biphenylene and bipyridine connected benzofuran compounds as novel regulators of kRAS transcription Cancer Research. 76: 2914-2914. DOI: 10.1158/1538-7445.Am2016-2914  0.388
2016 Morgan RK, Brooks TA. Abstract 1254: Small molecule targeting of the kRAS mid-G-quadruplex for potential pancreatic cancer therapeutics Cancer Research. 76: 1254-1254. DOI: 10.1158/1538-7445.Am2016-1254  0.35
2015 Morgan RK, Batra H, Gaerig VC, Hockings J, Brooks TA. Identification and characterization of a new G-quadruplex forming region within the kRAS promoter as a transcriptional regulator. Biochimica Et Biophysica Acta. PMID 26597160 DOI: 10.1016/J.Bbagrm.2015.11.004  0.395
2015 Morgan RK, Brooks TA, Rahman KM. Abstract 5419: Structure elucidation of G-quadruplex within the mid-region of the kRAS promoter and identification of stabilizing small molecules as promising transcriptional silencers Cancer Research. 75: 5419-5419. DOI: 10.1158/1538-7445.Am2015-5419  0.395
2015 Hao T, Brooks TA. Abstract 2110: Modulating NRAS mRNA translation by nucleic acid clamp-mediated stabilization of the 5′- UTR G-quadruplex Cancer Research. 75: 2110-2110. DOI: 10.1158/1538-7445.Am2015-2110  0.317
2015 Morgan R, Wadkins R, Brooks T. Abstract 1050: Effects of 5-hydroxymethylcytosine epigenetic modification on G-quadruplex and i-motif structure and stability within the VEGF promoter Cancer Research. 75: 1050-1050. DOI: 10.1158/1538-7445.Am2015-1050  0.332
2014 Bhavsar-Jog YP, Van Dornshuld E, Brooks TA, Tschumper GS, Wadkins RM. Epigenetic modification, dehydration, and molecular crowding effects on the thermodynamics of i-motif structure formation from C-Rich DNA Biochemistry. 53: 1586-1594. PMID 24564458 DOI: 10.1021/Bi401523B  0.319
2014 Hockings J, Brooks TA. Abstract A44: Identification of new, biologically relevant, G-quadruplexes formed within the critical promoter of kRAS as promising molecular targets Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A44  0.399
2013 Brown RV, Gaerig VC, Simmons T, Brooks TA. Helping Eve overcome ADAM: G-quadruplexes in the ADAM-15 promoter as new molecular targets for breast cancer therapeutics. Molecules (Basel, Switzerland). 18: 15019-34. PMID 24317528 DOI: 10.3390/Molecules181215019  0.418
2013 Hockings C, Greer KM, Brooks TA. Abstract 4374: Identification of novel, biologically relevant, G-quadruplexes formed within the critical promoter of kRAS as promising molecular targets. Cancer Research. 73: 4374-4374. DOI: 10.1158/1538-7445.Am2013-4374  0.436
2012 Boddupally PV, Hahn S, Beman C, De B, Brooks TA, Gokhale V, Hurley LH. Anticancer activity and cellular repression of c-MYC by the G-quadruplex-stabilizing 11-piperazinylquindoline is not dependent on direct targeting of the G-quadruplex in the c-MYC promoter. Journal of Medicinal Chemistry. 55: 6076-86. PMID 22691117 DOI: 10.1021/Jm300282C  0.373
2012 Gaerig VC, Jin X, Tabrizian T, Danford FL, Brooks TA. Abstract 4757: Design and optimization of linked nucleic acid (LNA) probes to detect the c-MYC G-quadruplex Cancer Research. 72: 4757-4757. DOI: 10.1158/1538-7445.Am2012-4757  0.4
2012 Kaiser CE, Gaerig VC, Hurley LH, Brooks TA. Abstract 1829: Small molecule stabilization of the kRAS promoter G-quadruplex as a target for novel pancreatic cancer therapeutics Cancer Research. 72: 1829-1829. DOI: 10.1158/1538-7445.Am2012-1829  0.338
2011 Brown RV, Danford FL, Gokhale V, Hurley LH, Brooks TA. Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. The Journal of Biological Chemistry. 286: 41018-27. PMID 21956115 DOI: 10.1074/Jbc.M111.274720  0.404
2011 Brown RV, Hurley LH, Brooks TA. Abstract 4422: Direct demonstration of c-MYC G-quadruplex stabilization in vitro: elucidating the CA46 system Cancer Research. 71: 4422-4422. DOI: 10.1158/1538-7445.Am2011-4422  0.391
2010 Brooks TA, Hurley LH. Targeting MYC Expression through G-Quadruplexes. Genes & Cancer. 1: 641-649. PMID 21113409 DOI: 10.1177/1947601910377493  0.382
2010 Brooks TA, Kendrick S, Hurley L. Making sense of G-quadruplex and i-motif functions in oncogene promoters. The Febs Journal. 277: 3459-69. PMID 20670278 DOI: 10.1111/J.1742-4658.2010.07759.X  0.35
2010 Qin Y, Fortin JS, Tye D, Gleason-Guzman M, Brooks TA, Hurley LH. Molecular cloning of the human platelet-derived growth factor receptor beta (PDGFR-beta) promoter and drug targeting of the G-quadruplex-forming region to repress PDGFR-beta expression. Biochemistry. 49: 4208-19. PMID 20377208 DOI: 10.1021/Bi100330W  0.302
2010 Brown RV, Gaerig VC, Fortin JS, Brooks TA. Abstract 3681: Helping Eve overcome ADAM: Characterization of the G-quadruplex in the ADAM15 core promoter Cancer Research. 70: 3681-3681. DOI: 10.1158/1538-7445.Am10-3681  0.441
2010 Gaerig VC, Fortin JS, Brown RV, Brooks TA. Abstract 1386: A novel approach to develop anti-VEGFR2/KDR therapeutics: characterizing and targeting the G-quadruplex Cancer Research. 70: 1386-1386. DOI: 10.1158/1538-7445.Am10-1386  0.403
2008 Brooks TA, Nametz N, Charles R, Davis TP. Diclofenac attenuates the regional effect of lambda-carrageenan on blood-brain barrier function and cytoarchitecture. The Journal of Pharmacology and Experimental Therapeutics. 325: 665-73. PMID 18305016 DOI: 10.1124/Jpet.107.135632  0.302
2007 McCaffrey G, Staatz WD, Quigley CA, Nametz N, Seelbach MJ, Campos CR, Brooks TA, Egleton RD, Davis TP. Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. Journal of Neurochemistry. 103: 2540-55. PMID 17931362 DOI: 10.1111/J.1471-4159.2007.04943.X  0.311
2007 Seelbach MJ, Brooks TA, Egleton RD, Davis TP. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. Journal of Neurochemistry. 102: 1677-90. PMID 17697052 DOI: 10.1111/J.1471-4159.2007.04644.X  0.319
2007 Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR. The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells Investigational New Drugs. 25: 115-122. PMID 17072745 DOI: 10.1007/S10637-006-9018-3  0.623
2005 Brooks TA, Hawkins BT, Huber JD, Egleton RD, Davis TP. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. American Journal of Physiology. Heart and Circulatory Physiology. 289: H738-43. PMID 15792985 DOI: 10.1152/Ajpheart.01288.2004  0.302
2005 Ojima I, Borella CP, Wu X, Bounaud PY, Oderda CF, Sturm M, Miller ML, Chakravarty S, Chen J, Huang Q, Pera P, Brooks TA, Baer MR, Bernacki RJ. Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents. Journal of Medicinal Chemistry. 48: 2218-28. PMID 15771464 DOI: 10.1021/Jm049483Y  0.696
2004 Brooks TA, Kennedy DR, Gruol DJ, Ojima I, Baer MR, Bernacki RJ. Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Research. 24: 409-15. PMID 15152938  0.684
2004 Minderman H, Brooks TA, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemotherapy and Pharmacology. 53: 363-9. PMID 15060738 DOI: 10.1007/S00280-003-0745-2  0.685
2003 Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ, Brooks T. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Molecular Cancer Therapeutics. 2: 1195-205. PMID 14617793  0.698
Show low-probability matches.